The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Open accessAbstract
Rituximab, an anti-CD20 monoclonal antibody, has been used to treat autoimmune disorders such as idiopathic thrombocytopenic purpura (ITP). However, its mechanisms of action as well as the effects on cellular immunity remain poorly defined. We investigated the changes of different peripheral blood T-cell subsets, the apoptosis profile, as well as the changes of T-cell receptor (TCR) β-variable (VB) region gene usage of CD4+ and CD8+ T-cell subpopulations following rituximab therapy. The study involved 30 patients with chronic ITP who received rituximab, of whom 14 achieved a durable (> 6 months) response. Compared with the control group, pretreatment abnormalities of T cells in ITP patients included an increase of the Th1/Th2 ratio and of the Tc1/Tc2 ratios (P < .001), increased expression of Fas ligand on Th1 and Th2 cells (P < .001), increased expression of Bcl-2 mRNA (P = .003) and decreased expression of bax mRNA (P = .025) in Th cells, and expansion of oligoclonal T cells with no preferential use of any TCR VB subfamily. These abnormalities were reverted in responders at 3 and 6 months after treatment, whereas they remained unchanged in nonresponders. Our findings indicate that in patients with ITP, response to B-cell depletion induced by rituximab is associated with significant changes of the T-cell compartment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
Olsson, B., Andersson, P.-O., Jernås, M., Jacobsson, S., Carlsson, B., Carlsson, L. M. S., & Wadenvik, H. (2003) · Nature Medicine · doi:10.1038/nm921 · Cited by 669
Arnold, D. M., Dentali, F., Crowther, M. A., Meyer, R. M., Cook, R. J., Sigouin, C., Fraser, G. A., Lim, W., & Kelton, J. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00006 · Cited by 557
Stasi, R., Pagano, A., Stipa, E., & Amadori, S. (2001) · Blood · doi:10.1182/blood.v98.4.952 · Cited by 549
Self-citationB-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
Semple, J., Milev, Y., Cosgrave, D., Mody, M., Hornstein, A., Blanchette, V, & Freedman, J. (1996) · Blood · doi:10.1182/blood.v87.10.4245.bloodjournal87104245 · Cited by 363
Cooper, N., Stasi, R., Cunningham‐Rundles, S., Feuerstein, M. A., Leonard, J. P., Amadori, S., & Bussel, J. B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04889.x · Cited by 336
Self-citationPanitsas, F. P., Theodoropoulou, M., Kouraklis, A., Karakantza, M., Theodorou, G. L., Zoumbos, N. C., Maniatis, A., & Mouzaki, A. (2004) · Blood · doi:10.1182/blood-2003-07-2268 · Cited by 264
Vallerskog, T., Gunnarsson, I., Widhe, M., Risselada, A., Klareskog, L., van Vollenhoven, R., Malmström, V., & Trollmo, C. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.08.016 · Cited by 240
Chakir, H., Wang, H., Lefebvre, D. E., Webb, J., & Scott, F. W. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00200-x · Cited by 194
Cited by
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., & Tedder, T. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36030 · Cited by 913
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Effector and regulatory B cells: modulators of CD4+ T cell immunity
Lund, F. E., & Randall, T. D. (2010) · Nature Reviews Immunology · doi:10.1038/nri2729 · Cited by 638
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Zufferey, A., Kapur, R., & Semple, J. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6020016 · Cited by 566
Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., & Bennett, C. L. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70161-5 · Cited by 447
Metadata
- Authors
- Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M. L., Trawinska, M. M., Cooper, N., & Amadori, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-10-15
- Volume
- 110
- Issue
- 8
- Pages
- 2924-2930
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2066976900
- Cited by
- 301
- References
- 19
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. https://app.cochat.ai/papers/10.1182/blood-2007-02-068999
- The paper
- Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M. L., Trawinska, M. M., Cooper, N., & Amadori, S. (2007). Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. https://doi.org/10.1182/blood-2007-02-068999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.